Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)

Phase 1

Completed

• Conditions: Ovarian Cancer; Cancer; Breast Cancer; Head and Neck Cancer; Non Small Cell Lung Cancer; Gastric Cancer; EGJ; Esophagogastric Junction Cancer; Urothelial Cancer; Melanoma
• Interventions: Biological: E-602; Biological: Cemiplimab

• Registration Number: NCT05259696
• Lead Sponsor: Palleon Pharmaceuticals, Inc.

Brief Summary

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.

Detailed Description

This study is being conducted to evaluate the safety, tolerability, PK, pharmacodynamics, and antitumor activity of E-602 in subjects with advanced cancers.

Phase 1 of the study consists of dose escalation cohorts of E-602 as a monotherapy and in combination with cemiplimab. Dose escalation will utilize a modified 3+3 design. Any Phase 1 cohort may be backfilled, up to a total of 15 subjects to obtain additional safety, PK, and pharmacodynamic data at a particular dose level. Phase 1 will treat subjects with melanoma, ovarian cancer, non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, breast cancer, gastric/esophagogastric junction (EGJ) cancer, head and neck cancer, or urothelial cancer. The safety and pharmacodynamic data will be evaluated to identify the maximum tolerated dose and recommended Phase 2 dose level for E-602 as monotherapy and in combination with cemiplimab.

Phase 2 consists of dose-expansion disease cohorts in subjects with 3 types of advanced tumors: melanoma, NSCLC, and a third type to be determined (ovarian, colorectal, pancreatic, breast, gastric/EGJ, head and neck, or urothelial) based on available data. Phase 2 includes cohorts of E-602 as monotherapy and E-602 in combination with camiplimab. For each cohort in Phase 2, Simon's minimax 2-stage design will be used.

The study is seeking to enroll a total of up to 273 subjects (up to 87 in Phase 1 and up to 186 in Phase 2). Subjects will participate in the study for about 16 months.

Study Timeline

• Study Start: 2022-02-11
• Study First Submitted: 2022-02-11
• Study First Submitted QC: 2022-02-22
• Study First Posted: 2022-02-28
• Primary Completion: 2024-10-24
• Study Completion: 2024-10-24
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-24
• Last Update Posted: 2025-03-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 69

Inclusion Criteria

1. Subjects with advanced or relapsed/refractory melanoma, ovarian cancer, NSCLC, colorectal cancer, pancreatic cancer, breast cancer, gastric/esophagogastric junction (EGJ) cancer, head and neck cancer, or urothelial cancer who have failed prior therapies.

   a. Subjects with melanoma, NSCLC, head and neck cancer, urothelial cancer, or mMSI-H or dMMR colorectal cancer must have had prior anti-PD-(L)1 pathway therapy and been deemed resistant (had progression on therapy or within 3 months of discontinuation of therapy).

2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

3. Subject has disease that is measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.

4. Adequate bone marrow, coagulation, renal function, and liver function as determined by laboratory tests

Key

Exclusion Criteria

1. For cohorts receiving E-602 and cemiplimab combination therapy:

   1. Prior moderate or severe hypersensitivity to cemiplimab or its formulation
   2. History of severe (≥ Grade 3) autoimmune complications or discontinuation due to toxicity following treatment with an anti-PD-(L)1 pathway therapy as a monotherapy, with the exception of asymptomatic Grade 3 elevations in lipase and/or amylase not associated with clinical manifestations of pancreatitis.
   3. Subject has an active autoimmune disease. The following are not exclusionary: vitiligo, type 1 diabetes, autoimmune endocrinopathies that are stable on hormone replacement therapy, or psoriasis that does not require systemic treatment.
   4. Previously received idelalisib.

2. History of age-related macular degeneration (AMD).

3. Recent surgery, treatment with another investigational agent, active infection, non-healing wound or uncontrolled bleeding/bleeding diathesis.

4. Received a vaccine or prior radiotherapy within 14 days prior to Cycle 1 Day 1.

5. Prior history of interstitial lung disease that required steroids or ≥ Grade 2 immune-related pneumonitis or has current non-infectious pneumonitis or interstitial lung disease. Subject has a history of ≥Grade 3 radiation pneumonitis, or Grade 2 radiation pneumonitis that has been active within the last 6 months.

6. Untreated brain metastases.

7. A known primary malignancy that is progressing or has required active treatment within the past 3 years.

8. Subject is taking the equivalent of >10 mg/day oral prednisone or on systemic immunosuppressive therapy.

9. Subject has had an allogeneic tissue or organ transplantation.

10. History of thromboembolic event unless the event occurred > 6 months from Cycle 1 Day 1 and the subject is on anti-coagulation treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Expansion - Monotherapy	E-602	Subjects will receive E-602 as monotherapy at the recommended Phase 2 dose determined in Phase 1.
Expansion - Combination	Cemiplimab	Subjects will receive E-602 in combination with cemiplimab. E-602 dose: Subjects will receive E-602 at the recommended Phase 2 dose determined in Phase 1 in combination with cemiplimab. Cemiplimab dose: 350 mg.
Dose Escalation - Combination	E-602	Subjects will receive E-602 in combination with cemiplimab. E-602 dose(s): Will be initiated at dose level(s) that have previously completed dosing and DLT assessments as monotherapy. Cemiplimab dose: 350 mg.
Dose Escalation - Combination	Cemiplimab	Subjects will receive E-602 in combination with cemiplimab. E-602 dose(s): Will be initiated at dose level(s) that have previously completed dosing and DLT assessments as monotherapy. Cemiplimab dose: 350 mg.
Expansion - Combination	E-602	Subjects will receive E-602 in combination with cemiplimab. E-602 dose: Subjects will receive E-602 at the recommended Phase 2 dose determined in Phase 1 in combination with cemiplimab. Cemiplimab dose: 350 mg.
Dose Escalation - Monotherapy	E-602	Subjects will receive E-602 as monotherapy. Planned monotherapy dose levels: 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg.

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (Phase 2)	12 Months	Objective response rate of confirmed complete response and partial response
Incidence of AEs and SAEs (Phase 1)	15 Months	Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Duration of Response (Phase 2)	16 Months	Duration of Response of confirmed complete response or partial response.
Progression Free Survival (Phase 2)	15 Months	Time from first study treatment dose until the first date when progressive disease (PD) is objectively documented or death from any cause
Overall Survival (Phase 2)	15 Months	Time from first study treatment dose until death
Dose-Limiting Toxicities (Phase 1)	21 days	Incidence of dose-limiting toxicities (DLTs) within a modified 3+3 trial design

Secondary Outcome Measures

Name	Time	Method
Progression Free Survival (Phase 1)	15 Months	Time from first dose to first evidence of radiographically detectable disease or death from any cause
Overall Survival (Phase 1)	15 Months	Time from first study treatment dose until death
Subjects with Antidrug Antibodies (Phase 1)	13 Months	Number and percentage of subjects who develop detectable antidrug antibodies
Objective Response Rate (Phase 1)	12 Months	Objective response rate of confirmed complete response and partial response using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and Immunotherapy Response Evaluation Criteria in Solid Tumors (iRECIST).
Duration of Response (Phase 1)	16 Months	Duration of Response of confirmed complete response or partial response
Incidence of AEs and SAEs (Phase 2)	15 Months	Incidence of adverse events (AEs) and serious adverse events (SAEs) graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0
Noncompartmental PK Parameters of E-602 (Phase 1)	12 Months	Area under the plasma concentration-time curve (AUC)
Noncompartmental PK Parameters of E-602 (Phase 2)	12 Months	Area under the plasma concentration-time curve (AUC)
Subjects with Antidrug Antibodies (Phase 2)	13 Months	Number and percentage of subjects who develop detectable antidrug antibodies

Trial Locations

Locations (13)

Virginia Cancer Specialists; 🇺🇸 Fairfax, Virginia, United States

University of Southern California; 🇺🇸 Los Angeles, California, United States

UC San Diego Moores Cancer Center; 🇺🇸 La Jolla, California, United States

START Midwest; 🇺🇸 Grand Rapids, Michigan, United States

Stanford Health Care; 🇺🇸 Stanford, California, United States

Roswell Park Comprehensive Cancer Center; 🇺🇸 Buffalo, New York, United States

Columbia University; 🇺🇸 New York, New York, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

University of Pittsburgh Medical Center; 🇺🇸 Pittsburgh, Pennsylvania, United States

NEXT Oncology; 🇺🇸 San Antonio, Texas, United States

Sarah Cannon Research Institute; 🇺🇸 Nashville, Tennessee, United States

Yale University Cancer Center; 🇺🇸 New Haven, Connecticut, United States

Providence Cancer Institute; 🇺🇸 Portland, Oregon, United States